Related Experiment Videos
A practical cost analysis of bivalirudin
1Saint Joseph's Hospital of Atlanta, Georgia 30342, USA. acompton@sjha.org
Pharmacotherapy
|June 18, 2002
Summary
Bivalirudin effectively reduces both bleeding and ischemic complications during percutaneous coronary intervention (PCI). Its use is cost-effective, offsetting its own expense by lowering overall medical costs associated with these complications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Percutaneous coronary intervention (PCI) carries significant risks of ischemic and bleeding complications.
- These complications lead to increased morbidity, mortality, and healthcare costs.
Purpose of the Study:
- To evaluate the effectiveness and cost-efficiency of bivalirudin in mitigating PCI-related complications.
- To assess the economic impact of bivalirudin on total medical costs.
Main Methods:
- Analysis of data from three clinical trials involving bivalirudin.
- Calculation of the number needed to treat (NNT) to avoid bleeding complications using data from the Bivalirudin Angioplasty Trial.
Main Results:
- Bivalirudin is the only antithrombotic agent demonstrated to reduce both ischemic and hemorrhagic complications in PCI.
- Cost models indicate that bivalirudin usage offsets its own cost through complication reduction.
Conclusions:
- Bivalirudin offers a dual benefit of reducing both ischemic and bleeding risks in PCI.
- The use of bivalirudin is economically advantageous, lowering overall healthcare expenditures related to PCI complications.